AJM OnlineClinical communication to the EditorSevere Hepatic Injury Caused by Orlistat
References (4)
- et al.
Orlistat associated subacute hepatic failure
J Hepatol
(2001) - et al.
Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis
Hepatology
(1997)
Cited by (17)
Susceptible genetic polymorphisms and their association with adverse effects of orlistat therapy
2021, Obesity MedicineCitation Excerpt :Morris et al., 2012). A 35-year-old woman who was moderately obese with sub-acute hepatic failure undergone liver transplantation was treated with orlistat 120 mg/day (Umemura et al., 2006). After three weeks, a usual laboratory check demonstrated severely impaired liver function.
Antiobesity effect of ethanolic extract of Ramulus mori in differentiated 3T3-L1 adipocytes and high-fat diet-induced obese mice
2020, Journal of EthnopharmacologyCitation Excerpt :In the case of GOT, the orlistat-treated group showed a significantly high level, and the GPT levels of the model group and the orlistat-treated group were significantly higher than those in the ERM-treated groups (Table 2). The results were consistent with the previously reported side effect of orlistat stating that orlistat treatment is associated with acute liver injury (Douglas et al., 2013; Umemura et al., 2006). There was no significant change in the concentrations of GOT and GPT in the ERM-treated groups compared with the same parameters in the negative control group, which suggests that ERM may not be toxic to the experimental animals at the concentrations used in this study.
Hepatotoxicity induced by herbs and medicines used to induce weight loss
2008, Gastroenterologia y HepatologiaPilot study of temporary controllable gastric pseudobezoars for dynamic non-invasive gastric volume reduction
2010, Physiological MeasurementBariatric embolization: a new and effective option for the obese patient?
2017, Expert Review of Gastroenterology and Hepatology